Compare SOTK & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | CLNN |
|---|---|---|
| Founded | 1975 | 2012 |
| Country | United States | United States |
| Employees | N/A | 79 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 79.1M |
| IPO Year | 1995 | N/A |
| Metric | SOTK | CLNN |
|---|---|---|
| Price | $5.30 | $5.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $33.75 |
| AVG Volume (30 Days) | 43.0K | ★ 52.0K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $20,909,315.00 | N/A |
| Revenue This Year | $4.02 | $17.64 |
| Revenue Next Year | $10.95 | $19,516.77 |
| P/E Ratio | $108.40 | ★ N/A |
| Revenue Growth | ★ 1.97 | N/A |
| 52 Week Low | $3.23 | $3.50 |
| 52 Week High | $6.24 | $13.50 |
| Indicator | SOTK | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 44.64 |
| Support Level | $4.69 | $4.53 |
| Resistance Level | $5.79 | $6.61 |
| Average True Range (ATR) | 0.35 | 0.31 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 52.53 | 51.20 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.